Good news!
"Last year, Chinese biotech firms developed over 1,250 new drugs: more than companies based in the European Union and around 200 shy of those in the United States. International restrictions on the region’s fast-growing sector — such as a US law that prevents federally funded pharmaceutical companies from working with certain Chinese companies — are prompting some in China to argue that the country should go it alone. That would be a backwards step — for China and the rest of the world ..."
"In biomedical science, China still lags behind the United States and Europe when it comes to fundamental research and conducting clinical trials involving investigators and participants from several countries. But the nation is now a global leader when it comes to drug development and manufacturing. And it is becoming increasingly important in frontier science.
Industry analysts estimate that China now accounts for 70–95% of the global supply chain for many essential pharmaceutical products, including ibuprofen and paracetamol.
In 2024, Chinese biotechnology firms developed more than 1,250 new drugs, surpassing the European Union and approaching the US total of roughly 1,440 ...
In 2018, China conducted only 9% of the clinical trials conducted by companies around the world. Now, it is responsible for about one-fifth of such trials ... And in the past few years, it has achieved several therapeutic milestones. ..."
China’s biotech boom: why the nation must collaborate to stay ahead "Increased geopolitical tensions are prompting some in China to argue that the country should go it alone in biotechnology. That would be a backwards step — for China and the rest of the world."
No comments:
Post a Comment